These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38724160)

  • 1. Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?
    Genecand L; Lador F; Montani D; Perneger T
    Chest; 2024 May; 165(5):e161. PubMed ID: 38724160
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.
    Nathan SD; Tapson VF; Elwing J; Rischard F; Mehta J; Shapiro S; Shen E; Deng C; Smith P; Waxman A
    Am J Respir Crit Care Med; 2022 Jan; 205(2):198-207. PubMed ID: 34767495
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Ravichandran A; Engel P; Bajwa A; Allen R; Feldman J; Argula R; Smith P; Rollins K; Deng C; Peterson L; Bell H; Tapson V; Nathan SD
    N Engl J Med; 2021 Jan; 384(4):325-334. PubMed ID: 33440084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?
    Piccari L; Wort SJ
    Thorax; 2024 Mar; 79(4):295-296. PubMed ID: 38307844
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension.
    Voswinckel R; Reichenberger F; Gall H; Schmehl T; Gessler T; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Ghofrani HA; Olschewski H
    Pulm Pharmacol Ther; 2009 Feb; 22(1):50-6. PubMed ID: 19071225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally.
    Behr J
    Am J Respir Crit Care Med; 2022 Jan; 205(2):144-145. PubMed ID: 34856106
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
    Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
    Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
    El-Kersh K; Smith JS
    Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Ferrantino M; White RJ
    Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
    Kumar P; Thudium E; Laliberte K; Zaccardelli D; Nelsen A
    Clin Pharmacokinet; 2016 Dec; 55(12):1495-1505. PubMed ID: 27286723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.
    Corboz MR; Li Z; Malinin V; Plaunt AJ; Konicek DM; Leifer FG; Chen KJ; Laurent CE; Yin H; Biernat MC; Salvail D; Zhuang J; Xu F; Curran A; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2017 Dec; 363(3):348-357. PubMed ID: 28904003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
    Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF
    Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.